Alfonso Gómez de Liaño

Dr. Alfonso Gómez de Liaño

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2017 in The Lancet Oncology
Verified
Journal Article
Closed access
EPEric Pujade-Lauraine
Eric Pujade-Lauraine
JLJonathan A Ledermann
Jonathan A Ledermann
FSFrédéric Selle
Frédéric Selle
VGVal Gebski
Val Gebski
RPRichard T Penson
Richard T Penson
IVIgnace Vergote
Ignace Vergote

1 February 2018 in European Urology
Verified
Journal Article
Closed access
BSBernadett Szabados
Bernadett Szabados
NDNick van Dijk
Nick van Dijk
YTYen Zhi Tang
Yen Zhi Tang
MHMichiel S. van der Heijden
Michiel S. van der Heijden
AWAkhila Wimalasingham
Akhila Wimalasingham
TPThomas Powles
Thomas Powles

1 February 2020 in European Urology
Verified
Journal Article
Closed access
ALAlfonso Gómez de Liaño
Alfonso Gómez de Liaño
NDNick van Dijk
Nick van Dijk
GRGuillermo de Velasco Oria de Rueda
Guillermo de Velasco Oria de Rueda
Andrea NecchiAndrea Necchi
Andrea Necchi
PLPernelle Lavaud
Pernelle Lavaud
MHMichiel S. Van der Heijden
Michiel S. Van der Heijden

24 May 2018 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
PBPedro Barata
Pedro Barata
ALAlfonso Gómez de Liaño
Alfonso Gómez de Liaño
PMPrateek Mendiratta
Prateek Mendiratta
VCValerie Elizabeth Crolley
Valerie Elizabeth Crolley
BSBernadett Szabados
Bernadett Szabados
BRBrian I. Rini
Brian I. Rini
The outcome of patients who progress on front-line immune-based combination regimens (IC) including immune checkpoint inhibitors (CPI) and receive subsequent systemic therapy is unknown. Retrospective analysis of consecutive patients with clear-cell mRCC who progressed on one of seven clinical trials investigating an IC and received ≥1 line of subsequent VEGFR TKI therapy. Thirty-three patients [median age 57 (37–77), 85% male, 73% ECOG 0] were included. For evaluable patients (N = 28), the best response to first subsequent therapy was 29% partial response, 54% stable disease, and 18% progressive disease. The median PFS (mPFS) for first subsequent therapy was 6.4 months (95% CI, 4.4–8.4); no difference in mPFS by prior type of IC (VEGFR TKI-CPI vs. CPI-CPI) was noted (p = 0.310). Significant AEs were observed in 30% of patients, more frequently transaminitis (9%). VEGFR TKIs have clinical activity in mRCC refractory to IC therapy, possibly impacted by the mechanism of prior combination therapy.

1 February 2021 in Cancer Treatment Reviews
Verified
Journal Article
Closed access
MRM. Rey-Cárdenas
M. Rey-Cárdenas
Félix Guerrero-RamosFélix Guerrero-Ramos
Félix Guerrero-Ramos
ALAlfonso Gómez de Liaño
Alfonso Gómez de Liaño
ACA. Carretero-González
A. Carretero-González
HCHelena Bote-de Cabo
Helena Bote-de Cabo
GVG. de Velasco
G. de Velasco

23 July 2026 in New England Journal of Medicine
Verified
Journal Article
Closed access
MGMatthew D. Galsky
Matthew D. Galsky
BVBegoña P. Valderrama
Begoña P. Valderrama
MMMarco Maruzzo
Marco Maruzzo
AFAlbert Font
Albert Font
TCTudor Ciuleanu
Tudor Ciuleanu
ALAlfonso Gómez de Liaño
Alfonso Gómez de Liaño
Neoadjuvant cisplatin-based chemotherapy is a standard therapy for muscle-invasive bladder cancer. The efficacy and safety of neoadjuvant and adjuvant (perioperative) enfortumab vedotin-pembrolizumab as compared with neoadjuvant cisplatin-based chemotherapy in persons with this cancer are unclear. We conducted a phase 3, open-label, randomized trial involving adults with muscle-invasive bladder cancer eligible for cisplatin-based chemotherapy and radical cystectomy with pelvic lymph-node dissection (cystectomy). Participants were assigned to receive neoadjuvant enfortumab vedotin-pembrolizumab (4 cycles; enfortumab vedotin [1.25 mg per kilogram of body weight on days 1 and 8] and pembrolizumab [200 mg on day 1] every 3 weeks), cystectomy, and 5 cycles of enfortumab vedotin and 13 cycles of pembrolizumab as adjuvant therapy or to receive neoadjuvant cisplatin-gemcitabine (4 cycles; cisplatin [70 mg per square meter of body-surface area on day 1] plus gemcitabine [1000 mg per square meter on days 1 and 8] every 3 weeks) and cystectomy. The primary end point was event-free survival; key secondary end points were overall survival and pathological complete response. Safety was assessed. A total of 405 participants were assigned to receive enfortumab vedotin-pembrolizumab and 403 to receive cisplatin-gemcitabine. The median time from randomization to the data-cutoff date was 33.6 months (range, 22.5 to 53.6). A total of 86.7% of the participants in the enfortumab vedotin-pembrolizumab group and 89.6% of those in the cisplatin-gemcitabine group underwent cystectomy. At 2 years, estimated event-free survival was 79.4% with enfortumab vedotin-pembrolizumab and 66.2% with cisplatin-gemcitabine (hazard ratio for an event or death, 0.53; 95% confidence interval [CI], 0.41 to 0.70; P<0.001); estimated overall survival was 86.9% and 81.3%, respectively (hazard ratio for death, 0.65; 95% CI, 0.48 to 0.89; two-sided P = 0.006). A pathological complete response occurred in 55.8% and 32.5% of the participants (P<0.001). The incidence of grade 3 or higher adverse events of any cause was 75.7% with enfortumab vedotin-pembrolizumab and 67.2% with cisplatin-gemcitabine. Among participants with muscle-invasive bladder cancer eligible for cisplatin-based chemotherapy, perioperative enfortumab vedotin-pembrolizumab led to significantly better event-free and overall survival outcomes and a significantly higher incidence of pathological complete response than neoadjuvant cisplatin-gemcitabine, but with more adverse events of grade 3 or higher. (Funded by Merck Sharp and Dohme and others; KEYNOTE-B15/EV-304 ClinicalTrials.gov number, NCT04700124.).